Gopi Manthripragada, MD
Cardiovascular Disease · Boston, MANPI 1447441209
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Medtronic at 28.0% of the total. 2025 is the largest year on record at $1,493, more than ten times the $15 reported in 2019.
Across 36 payments — averaging $75.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$760
- Teleflex LLC$737
- Cathworks, Inc.$302
- Recor Medical Inc$205
- Abbott$189
- Abiomed$173
- plus $347 from 7 others
Across 17 payments — averaging $4931.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$77K
- Cathworks, Inc.$7K
- Abbott$53
What the payments were for
- Food & beverage$2,715100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 11 | $760 |
| Teleflex LLC | 6 | $737 |
| Cathworks, Inc. | 1 | $302 |
| Recor Medical Inc | 2 | $205 |
| Abbott | 7 | $189 |
| Abiomed | 1 | $173 |
| Shockwave Medical, Inc | 1 | $93 |
| Seigla Medical, Inc. | 1 | $86 |
| Boston Scientific | 1 | $72 |
| Philips North America LLC | 2 | $39 |
| Cardiva Medical, Inc. | 1 | $24 |
| Terumo Medical Corporation | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MANTA$383
- ONYX FRONTIER$360
- FFRangio$302
- PARADISE RENAL DENERVATION SYSTEM$183
- SYMPLICITY G3$174
- Impella$173
- COROFLOW$100
How this compares
$2,715 in reported general payments places this provider in the 60th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 25 | $13,475 |
| Atorvastatin Calcium | 38 | $489 |
| Metoprolol Succinate | 39 | $484 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $164 |
| Rosuvastatin Calcium | 12 | $133 |
| Losartan Potassium | 11 | $128 |
| Spironolactone | 11 | $95 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.